The 7 most recent market catalysts affecting $IPHA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 17, 2026
Corporate Catalyst
Neutral
Impact 55
BTIG Reiterates Buy on Innate Pharma, Maintains $9 Price Target
BTIG analyst Jeet Mukherjee reiterated a 'Buy' rating and maintained a $9 price target for Innate Pharma (IPHA). This action signals continued confidence from a prominent investmen…
Sep 17, 2026
Corporate Catalyst
Bearish
Impact 92
Innate Pharma H1 EPS $(0.24) Misses $(0.16) Estimate, Sales $6.583M Miss $9.100M Estimate
Innate Pharma's H1 earnings report indicates a significant underperformance compared to analyst expectations, with EPS missing by 50% and sales by 27.66%. While the company did sho…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 75
Innate Pharma shares are trading higher after BTIG maintained its Buy rating on the stock and raised its price target from $8 to $9.
This headline represents a significant positive catalyst for Innate Pharma. Analyst upgrades, especially with a raised price target, often signal increased institutional confidence…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Innate Pharma, Raises Price Target to $7
HC Wainwright & Co. analyst Swayampakula Ramakanth has maintained a 'Buy' rating on Innate Pharma (IPHA) and raised the price target from $5 to $7. This upgrade in the price target…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 85
Innate Pharma shares are trading higher after the company announced it has entered into a strategic partnership with Swedish Orphan Biovitrum AB to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma.
This announcement is a significant positive catalyst for Innate Pharma (IPHA) as it secures a partner and funding for a critical Phase 3 study, reducing financial burden and increa…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 85
Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapy
Innate Pharma (IPHA) has forged a strategic partnership with Swedish Orphan Biovitrum AB (Sobi) for its lead asset, lacutamab, targeting a rare form of skin cancer. This collaborat…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 65
Innate Pharma Completes Phase 1 Enrollment Of Nectin-4 Exatecan ADC IPH4502, Guiding Dose Optimization With Year-End Preliminary Data Readout
Innate Pharma announced the completion of enrollment for its Phase 1 IPH4502-101 study, a significant milestone in drug development. The preliminary data, expected by year-end, wil…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.